HPP2003-3

DRUG3 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

Hypertension

Phase 2

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

CompletedNCT04959305

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2021-04-22End: 2022-02-28Updated: 2022-07-14

Phase 3

A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

CompletedNCT05362110

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2022-05-16End: 2023-06-05Updated: 2023-09-26

A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension

CompletedNCT06438172

Hanmi Pharmaceutical Company LimitedHypertension

Start: 2024-03-25End: 2024-12-02Updated: 2025-02-19

Related Papers

SINGLE-PILL COMBINATION OF THIRD-DOSE TRIPLE ANTIHYPERTENSIVE THERAPY VERSUS STANDARD-DOSE MONOTHERAPY IN PATIENTS WITH MILD TO MODERATE HYPERTENSION

Journal of Hypertension2024-05-011 citations